Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;13(3):545-555.
doi: 10.1002/2211-5463.13566. Epub 2023 Feb 12.

The NLRP3 inflammasome - interleukin 1β axis in uveal melanoma

Affiliations

The NLRP3 inflammasome - interleukin 1β axis in uveal melanoma

Victor S M C Correa et al. FEBS Open Bio. 2023 Mar.

Abstract

Uveal melanoma (UM) is the most common primary intraocular cancer in the adult population. Recent studies suggested that the NLRP3 inflammasome could be a therapeutic target for cutaneous melanoma (CM), but the role of NLRP3 in UM remains unknown. Here, we analyzed the NLRP3-IL-1β axis in 5 UM and 4 CM cell lines. Expression of NLRP3 mRNA in UM and CM was low, and expression in UM was lower than in CM (P < 0.001). NLRP3 protein levels were below detection limit for all cell lines. UM exhibited lower baseline IL-1β secretion than CM, especially when compared to the Hs294t cell line (P < 0.05). Bioinformatic analysis of human tumor samples showed that UM has significantly lower expression of NLRP3 and IL-1β compared with CM. In conclusion, our work shows evidence of extremely low NLRP3 expression and IL-1β secretion by melanoma cells and highlight differences between CM and UM.

Keywords: IL-1; NLRP3; inflammasome; melanoma; skin; uveal.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Uveal melanoma has lower NLRP3 expression compared with cutaneous melanoma. (A) NLRP3 mRNA expression levels of UM and CM cell lines measured by qPCR. (B) Comparison of NLRP3 mRNA expression of melanoma cell lines with monocyte cell line THP‐1. (C, D) NLRP3 protein expression analysis by western blotting in melanoma cell lines and the positive control THP‐1 at 42 s of membrane exposure. Saturated pixels are highlighted in red. (E, F) Overexposure of the same membrane at 10 min. (G) Coomassie blue staining of the membrane. Statistical significance was analyzed with ANOVA followed by post hoc Tukey HSD test. All values are expressed as mean ± SEM (n = 3).
Fig. 2
Fig. 2
Uveal melanoma has minimal baseline secretion of IL‐1β. (A) Baseline secretion levels of IL‐1β by melanoma cell lines. (B, C) IL‐1β precursor (pro‐IL‐1β) protein expression analysis by WB in melanoma cell lines and the positive control (THP‐1‐derived macrophage) at 204 s of membrane exposure. Saturated pixels are highlighted in red. (D, E) Overexposure of the same membrane at 10 min. A faint band on OCM3 is indicated by the blue arrow. (F) Coomassie blue staining of the membrane. Statistical significance was analyzed with ANOVA followed by post hoc Tukey HSD test. All values are expressed as mean ± SEM (n = 5).
Fig. 3
Fig. 3
Bioinformatic analysis from human samples reveals the low expression of NLRP3 and IL‐1β on uveal melanoma samples and normal choroidal melanocytes. (A, B) Analysis of UM and CM gene expression levels from the Cancer Genome Atlas (TCGA) database. UM cases show significantly lower levels of NLRP3 and IL‐1β compared with CM. (C) Single‐cell clustering of normal human choroidal tissue showing the heatmap of NLRP3 (blue) and IL‐1β (red) co‐expression. Melanocytes (green circle) have low expression of both genes. (D, E) Reclustering of melanocytes reveals that most cells do not express NLRP3 or IL‐1β. Statistical significance was analyzed with Mann–Whitney U test. Outliers are marked with X.

Similar articles

Cited by

References

    1. Kaliki S and Shields CL (2017) Uveal melanoma: relatively rare but deadly cancer. Eye 31, 241–257. - PMC - PubMed
    1. Jager MJ, Shields CL, Cebulla CM, Abdel‐Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort RN, Jia R, Shields JA et al. (2020) Uveal melanoma. Nat Rev Dis Primers 6, 18–20. - PubMed
    1. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA et al. (2009) Metastasis of uveal melanoma millimeter‐by‐millimeter in 8033 consecutive eyes. Arch Ophthalmol 127, 989–998. - PubMed
    1. Garg G, Finger PT, Kivelä TT, Simpson R, Gallie BL, Saakyan S, Amiryan AG, Valskiy V, Chin KJ, Katerina S et al. (2022) Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol 106, 510–517. - PMC - PubMed
    1. Collaborative Ocular Melanoma Study Group (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Arch Ophthalmol 123, 1639–1643. - PubMed

Publication types

MeSH terms

Substances